Senti Biosciences Holdings Inc.
Organization details
- Legal name
- Senti Biosciences Holdings Inc.
- Former names
- Senti Biosciences, Inc. Dynamics Special Purpose Corp.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- SNTI
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001854270
- EIN
- 86-2437900
Board of directors
-
Brenda Cooperstone · DirectorSince 2023
-
Bryan Daniel Baum · DirectorSince 2025
-
Donald F. Tang · DirectorSince 2024
- Since 2023
-
Feng Hsiung · DirectorSince 2025
-
Fran Schulz · DirectorSince 2024
-
James J. Collins · DirectorSince 2023
-
Omid Farokhzad · DirectorSince 2023
-
Susan D. Berland · DirectorSince 2023
-
Timothy K. Lu · Director · CEOSince 2023
Chief executives
Director election results
Annual meeting of October 15, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.8%
-
99.0%
-
99.1%
Board connections
5 of this board's directors also sit on 8 other boards. 7 are in the same sector.
-
Edap TMS S.A. Same sectorvia Fran Schulz
-
Fulcrum Therapeutics Inc. Same sectorvia James J. Collins
-
Lexeo Therapeutics Inc. Same sectorvia Brenda Cooperstone
-
MBX Biosciences Inc. Same sectorvia Edward T. Mathers
-
OnKure Therapeutics Inc. Same sectorvia Edward T. Mathers
-
Rhythm Pharmaceuticals Inc. Same sectorvia Edward T. Mathers
- via Omid Farokhzad
-
Trevi Therapeutics Inc. Same sectorvia Edward T. Mathers
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 21, 2026 | Timothy K. Lu Director, Officer (CEO) | Shares withheld for tax | −157,312 | — | — |
| Oct 21, 2026 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Shares withheld for tax | −19,953 | — | — |
| Mar 9, 2026 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Shares withheld for tax | −10,757 | — | — |
| Mar 9, 2026 | Timothy K. Lu Director, Officer (CEO) | Shares withheld for tax | −80,666 | — | — |
| Feb 2, 2026 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Shares withheld for tax | −1,384 | — | — |
| Feb 2, 2026 | Timothy K. Lu Director, Officer (CEO) | Shares withheld for tax | −4,191 | — | — |
| Mar 10, 2025 | Celadon Partners SPV 24 10% owner | Derivative conversion | +9,777,000 | — | — |
| Mar 10, 2025 | Florence Anthony A. Jr. 10% owner | Derivative conversion | +3,333,000 | — | — |
| Mar 10, 2025 | Bayer US Holding LP 10% owner | Derivative conversion | +2,222,000 | — | — |
| Mar 10, 2025 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Derivative conversion | +33,000 | $2.25 | $74,250 |
| Mar 7, 2025 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Grant or award | +78,363 | — | — |
| Mar 7, 2025 | Timothy K. Lu Director, Officer (CEO and Interim PFO and PAO) | Grant or award | +642,358 | — | — |
| Feb 6, 2025 | Timothy K. Lu Director, Officer (CEO) | Open-market sale | −545 | $4.36 | $2,376 |
| Feb 6, 2025 | Rajangam Kanya Officer (Pres. & Chief Med. & Dev. Off.) | Open-market sale | −182 | $4.37 | $795 |
| Feb 4, 2025 | Timothy K. Lu Director, Officer (CEO) | Open-market sale | −3,922 | $4.07 | $15,963 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Senti Biosciences Holdings Inc.
Who is the CEO of Senti Biosciences Holdings Inc.?
Timothy K. Lu is Senti Biosciences Holdings Inc.'s CEO and President.
How many directors are on Senti Biosciences Holdings Inc.'s board?
Senti Biosciences Holdings Inc.'s board has 10 directors: Brenda Cooperstone, Bryan Daniel Baum, Donald F. Tang, Edward T. Mathers, Feng Hsiung, Fran Schulz, James J. Collins, Omid Farokhzad, Susan D. Berland and Timothy K. Lu.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="senti-biosciences-holdings-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.